Source: Kapitales Research

Highlights

• Cyclopharm Limited reported record first-half FY26 revenue of approximately AU$17.1 million, reflecting around 11% year-on-year growth, driven by accelerating US Technegas® adoption.
• Revenue-generating US Technegas® sites increased to 70, while the commercial pipeline expanded to more than 1,670 engaged locations, strengthening long-term recurring revenue potential.
• Near-term US installation guidance has been deferred, but the company continues targeting more than 2,000 revenue-generating US installations over the medium-term following approval of updated international clinical guidelines.

Can Strong Revenue Growth Offset the Delay?

Cyclopharm Limited (ASX: CYC) has attracted market attention after reporting record first-half revenue growth while providing an update on its expanding US commercial rollout. The company's shares traded at a CMP of AU$0.520, as investors assessed strong operational momentum against a revised timeline for achieving its short-term US installation target. Despite the guidance adjustment, Cyclopharm continues to strengthen its position in the rapidly growing nuclear medicine imaging market through its flagship Technegas® platform and expanding recurring revenue base.

Record Revenue and Expanding US Footprint

Cyclopharm expects first-half FY26 global revenue of approximately AU$17.1 million, representing around 11% year-on-year growth and marking the strongest half-year revenue performance in the company's history. US Technegas® revenue is forecast to increase around 73% year-on-year to approximately AU$2.1 million, while revenue from international markets outside the US is expected to rise around 13% to approximately AU$7.2 million. Overall Technegas® revenue is projected to reach approximately AU$9.4 million, reflecting around 22% growth compared to the prior corresponding period.

The company has also expanded its US commercial presence, increasing revenue-generating primary installations to 70 sites, up from 50 sites reported in May 2026. Cyclopharm's commercial pipeline now exceeds 1,670 actively engaged locations, highlighting significant future expansion opportunities across hospitals and healthcare networks.

Clinical Milestone Supports Long-Term Strategy

Cyclopharm confirmed that updated international lung scintigraphy guidelines have received final approval and are awaiting publication. The company believes these guidelines, which recognise Technegas® as the preferred ventilation imaging agent, will support wider adoption across the United States and international markets.

Although publication delays have pushed the company's target of 250–300 revenue-generating US installations beyond 31 December 2026, management has reaffirmed its medium-term objective of exceeding 2,000 US installations. Cyclopharm also finished June 2026 with an estimated cash balance of approximately AU$12.2 million and believes the business has moved beyond peak cash burn as recurring consumable revenue continues to grow.

Will the Next Catalyst Unlock Further Upside?

Cyclopharm's latest update highlights a business continuing to execute despite temporary timing challenges. Record revenue growth, an expanding installed base, increasing recurring income and broader clinical validation provide encouraging signs for the company's long-term outlook. While investors may remain cautious until the revised installation timeline gains momentum, the upcoming publication of international clinical guidelines could become the catalyst that accelerates commercial adoption and shapes the company's next phase of growth.

Note- All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au